QRxPharma hits on right dose
20 April, 2009 by Kate McDonaldQRxPharma completes Phase III dose pilot for opioids
Progen targets epigenetics
20 April, 2009 by Kate McDonaldProgen working on polyamine analogues for DNA demethylases, cell proliferation
Fermiscan and Polartechnics to merge
20 April, 2009 by Kate McDonaldTwo Sydney diagnostics company to form Novus Diagnostics
Fight of the honeybees
16 April, 2009 by Kate McDonaldSpanish researchers may have found a cure for honeybee colony collapse disorder
Australian biotech market today 15.04.09
15 April, 2009 by Kate McDonaldAcrux, Atcor, Cellestis, Pharmaxis, Mesoblast, Circadian, Alchemia
Acuvax cashes in RESprotect
15 April, 2009 by Kate McDonaldAcuvax divests small holding in German developer of pancreatic cancer drug
Australian biotech market today 14.04.09
14 April, 2009 by Kate McDonaldCellestis, ChemGenex, Mesoblast, Pharmaxis, Novogen, Probiotec, LabTech Systems
Canadian swine for Stirling
14 April, 2009 by Kate McDonaldStirling Products signs Canadian research agreement for R-salbutamol
Australian biotech market today 09.04.09
09 April, 2009 by Kate McDonaldGenera Biosystems, ChemGenex, Pharmaxis, LCT, pSivida, Bionomics, Mesoblast
How will biotech survive the GFC?
09 April, 2009 by Kate McDonaldThe biotechnology industry is in crisis on a global scale, so what can the industry do to help itself, and is government going to come to the rescue?
Australian biotech market today 08.04.09
08 April, 2009 by Kate McDonaldPharmaxis, Novogen, Progen, IDT, Clinuvel
Australian biotech market today 07.04008
07 April, 2009 by Kate McDonaldCellestis, Mesoblast, Tissue Therapies, Progen, Probiotec
Australian biotech market today 03.04.09
03 April, 2009 by Staff WritersStarpharma, Atcor, Bionomics, Circadian, CSL, Cochlear, Mesoblast, Pharmaxis
How to save the Australian biotechnology industry
02 April, 2009 by Kate McDonaldSaving biotech, growing muscle, finding flukes and Merv Jacobson speaks, all in the March/April 2009 issue of Australian Life Scientist, out now
